Pfizer Inc. (PFE)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pfizer Inc.  (“Pfizer” or the “Company”) (NYSE: PFE). Investors who purchased Core Scientific securities are encouraged to obtain additional information and assist the investigation.​

The investigation concerns whether Pfizer and certain of its officers and/or directors have violated federal securities laws.

On October 26, 2022,Bloomberg reported that Italian authorities are investigating Pfizer for allegedly hiding profits of at least €1.2 billion by transferring money to business units in other countries, including the U.S. and the Netherlands, to avoid taxes.  The probe began in February and covers 2017 through 2019.  On this news, Pfizer’s stock price fell $0.32 per share, or 0.69%, to close at $45.74 per share on October 27, 2022.

If you are aware of any facts relating to this investigation or purchased Pfizer shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.